ArticleBMC medical genomics2026
Efficient differential latent network analysis: applications to colon cancer.
Article in BMC medical genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundColon cancer (CC) presents significant molecular heterogeneity, complicating our understanding of its initiation and progression. Identifying CC-associated genes and their interactions is crucial for improving diagnostics and therapeutics. However, current gene analysis methods struggle to holistically capture complex gene interactions due to their inherent complexity.
methodWe propose a novel, simple, and scalable method called EFFICIENT DIFFERENTIAL LATENT NETWORK ANALYSIS (EDLNA) for detecting alterations in gene interactions using latent co-expression patterns. Our approach applies non-negative matrix factorization to construct separate latent gene networks for normal and cancer samples. We then identify differential interactions, followed by protein-protein interaction network and transcription factor (TF) analyses to detect functional modules and regulatory relationships.
resultsWe evaluated EDLNA against conventional methods using both simulated and colon cancer gene expression data (GSE44076, GSE50760). In simulation studies, EDLNA was significantly faster among differential network analysis techniques while maintaining comparable accuracy. When applied to colon cancer data, our method outperformed differential gene expression analysis in identifying biologically relevant gene clusters and stage-specific traits.
conclusionsEDLNA provides an efficient and scalable framework for identifying stage-specific gene interactions that bridge molecular mechanisms with clinical phenotypes. These findings underscore its potential for discovering novel biomarkers and advancing targeted therapies in colon cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.